355 related articles for article (PubMed ID: 32483919)
21. Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.
Kivitz AJ; Gutierrez-Ureña SR; Poiley J; Genovese MC; Kristy R; Shay K; Wang X; Garg JP; Zubrzycka-Sienkiewicz A
Arthritis Rheumatol; 2017 Apr; 69(4):709-719. PubMed ID: 27748083
[TBL] [Abstract][Full Text] [Related]
22. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
[TBL] [Abstract][Full Text] [Related]
24. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
Kawalec P; Mikrut A; Wiśniewska N; Pilc A
Clin Rheumatol; 2013 Oct; 32(10):1415-24. PubMed ID: 23877486
[TBL] [Abstract][Full Text] [Related]
25. Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis.
Zhang X; Liang F; Yin X; Xiao X; Shi P; Wei D; Yao L; Wang Q; Chen Y
Clin Rheumatol; 2014 Feb; 33(2):165-73. PubMed ID: 24389749
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Iwasaki M; Katayama K; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Shiomi T; Yamada E; van der Heijde D
Ann Rheum Dis; 2019 Oct; 78(10):1305-1319. PubMed ID: 31350269
[TBL] [Abstract][Full Text] [Related]
27. Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis.
Buckley F; Finckh A; Huizinga TW; Dejonckheere F; Jansen JP
J Manag Care Spec Pharm; 2015 May; 21(5):409-23. PubMed ID: 25943002
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
Gaujoux-Viala C; Nam J; Ramiro S; Landewé R; Buch MH; Smolen JS; Gossec L
Ann Rheum Dis; 2014 Mar; 73(3):510-5. PubMed ID: 24395555
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2020 Jun; 58(6):293-298. PubMed ID: 32301699
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of peficitinib in rheumatoid arthritis.
Kaneko Y
Mod Rheumatol; 2020 Sep; 30(5):773-778. PubMed ID: 32643492
[TBL] [Abstract][Full Text] [Related]
31. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
32. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Song GG; Lee YH
Z Rheumatol; 2020 Feb; 79(1):103-111. PubMed ID: 30725185
[TBL] [Abstract][Full Text] [Related]
34. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
Claxton L; Jenks M; Taylor M; Wallenstein G; Mendelsohn AM; Bourret JA; Singh A; Moynagh D; Gerber RA
J Manag Care Spec Pharm; 2016 Sep; 22(9):1088-102. PubMed ID: 27579831
[TBL] [Abstract][Full Text] [Related]
35. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
Lee YH; Song GG
Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
[TBL] [Abstract][Full Text] [Related]
36. Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.
Scott LJ
Drugs; 2013 Jun; 73(8):857-74. PubMed ID: 23716132
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Lee YH; Song GG
Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
[TBL] [Abstract][Full Text] [Related]
38. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
[TBL] [Abstract][Full Text] [Related]
39. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]